このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Carmat マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Stephane Piat

最高経営責任者

€2.4m

報酬総額

CEO給与比率	19.1%
CEO在任期間	8.1yrs
CEOの所有権	0.5%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	6.5yrs

経営陣の近況

Increases to Carmat SA's (EPA:ALCAR) CEO Compensation Might Cool off for now

May 05

Recent updates

CEO報酬分析

Carmat の収益と比較して、Stephane Piat の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-€53m
Mar 31 2024	n/a	n/a	-€54m
Dec 31 2023	€2m	€459k	-€54m
Sep 30 2023	n/a	n/a	-€54m
Jun 30 2023	n/a	n/a	-€54m
Mar 31 2023	n/a	n/a	-€54m
Dec 31 2022	€3m	€434k	-€54m
Sep 30 2022	n/a	n/a	-€58m
Jun 30 2022	n/a	n/a	-€62m
Mar 31 2022	n/a	n/a	-€62m
Dec 31 2021	€2m	€425k	-€62m
Sep 30 2021	n/a	n/a	-€52m
Jun 30 2021	n/a	n/a	-€42m
Mar 31 2021	n/a	n/a	-€40m
Dec 31 2020	€3m	€418k	-€37m
Sep 30 2020	n/a	n/a	-€38m
Jun 30 2020	n/a	n/a	-€40m
Mar 31 2020	n/a	n/a	-€41m
Dec 31 2019	€2m	€412k	-€43m
Sep 30 2019	n/a	n/a	-€45m
Jun 30 2019	n/a	n/a	-€47m
Mar 31 2019	n/a	n/a	-€44m
Dec 31 2018	€8m	€409k	-€42m
Sep 30 2018	n/a	n/a	-€38m
Jun 30 2018	n/a	n/a	-€34m
Mar 31 2018	n/a	n/a	-€32m
Dec 31 2017	€3m	€397k	-€29m

報酬と市場: Stephaneの総報酬 ($USD 2.68M ) は、 French市場 ($USD 412.66K ) の同規模の企業の平均を上回っています。

報酬と収益: Stephaneの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Stephane Piat (53 yo)

8.1yrs

在職期間

€2,397,006

報酬

Mr. Stéphane Piat has been Chief Executive Officer of Carmat SA since September 1, 2016 and has been its Director since April 27, 2017. Mr. Piat is an acknowledged specialist in the medical device busines...

取締役

名称	ポジション	在職期間	報酬	所有権
Stephane Piat	CEO & Director	7.5yrs	€2.40m	0.49% € 261.3k
Pierre Bastid	Independent Chairman	6.5yrs	€16.00k	データなし
Michael Mack	Independent Director	7.8yrs	€20.00k	データなし
Friedrich-Wilhelm Mohr	Member of the Scientific Committee	no data	データなし	データなし
Alain Carpentier	Honorary President	5.6yrs	€1.50k	データなし
Gunther Laufer	Member of the Scientific Committee	no data	データなし	データなし
Paul Mohacsi	Member of the Scientific Committee	no data	データなし	データなし
Edoardo Gronda	Member of the Scientific Committee	no data	データなし	データなし
Mark Slaughter	Member of the Scientific Committee	no data	データなし	データなし
Jean-Luc Lemercier	Independent Director	7.8yrs	€8.00k	データなし
John Hernandez	Independent Director	3.4yrs	€20.00k	データなし
David Coti	Director	3.4yrs	€4.00k	データなし

6.5yrs

平均在職期間

62.5yo

平均年齢

経験豊富なボード: ALCARの取締役会は経験豊富であると考えられます ( 7.2年の平均在任期間)。

Carmat マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Insufficient new directors

Carmat SA Announces Board Changes

Carmat SA Appoints Alexandre Conroy as Chairman of the Board of Directors

Insufficient new directors

Insufficient new directors

Increases to Carmat SA's (EPA:ALCAR) CEO Compensation Might Cool off for now

Recent updates

Price target decreased by 7.5% to €8.43

Consensus revenue estimates fall by 39%

Carmat SA Ordinary Shares to Be Deleted from OTC Equity

Carmat SA to Report First Half, 2024 Results on Sep 30, 2024

Price target decreased by 9.3% to €11.18

Consensus EPS estimates fall by 10%

Insufficient new directors

Carmat SA Announces Board Changes

Price target decreased by 8.9% to €12.33

New major risk - Shareholder dilution

Carmat SA has filed a Follow-on Equity Offering in the amount of €62.57559 million.

CARMAT Continues to Build on Its Momentum in the EFICAS Study

Full year 2023 earnings: Revenues miss analyst expectations

Calculating The Intrinsic Value Of Carmat SA (EPA:ALCAR)

CARMAT Provides Revenue Guidance for the Year 2024

Now 20% overvalued

Carmat SA to Report Fiscal Year 2023 Results on Apr 24, 2024

Consensus revenue estimates fall by 11%

Price target decreased by 10% to €16.93

Consensus revenue estimates increase by 16%, EPS downgraded

Forecast to breakeven in 2026

Carmat SA announced that it expects to receive €15.000002 million in funding

Carmat Sa Provides Earnings Guidance for the Year 2024

Consensus revenue estimates increase by 19%

Forecast to breakeven in 2026

Carmat Announces Software Enhancement Which Significantly Improves the Safety Profile of Its Aeson®? Artificial Heart

CARMAT Announces the First Implant of the Aeson® Artificial Heart in a Patient Suffering from a Cardiac Tumor

CARMAT Presented Its Progress on the EFICAS Clinical Study at the 36th Journées de La Pitié in Paris

Carmat SA announced that it has received €6.999991 million in funding from Lohas S.à R.L., Sante Holdings S.R.L., Therabel Healthcare Investment SA

New minor risk - Market cap size

New major risk - Financial position

First half 2023 earnings released

Carmat SA Provides Sales Guidance for the Fourth Quarter 2023

No longer forecast to breakeven

Price target decreased by 12% to €24.10

No longer forecast to breakeven

Consensus revenue estimates increase by 21%

Carmat SA to Report Fiscal Year 2022 Results on Feb 23, 2023

Carmat Announces the First Implantation of Aeson® Within the Framework of the Eficas Clinical Study in France

Carmat SA Appoints Alexandre Conroy as Chairman of the Board of Directors

Carmat SA Announces the Resumption of Commercial Implants of Its Aeson(R) Artificial Heart Is Now Effective

Carmat SA Receives Regulatory Approvals to Resume its Clinical Study in France

CARMAT Receives the Necessary Regulatory Approvals to Resume Aeson Commercial Implants

Consensus revenue estimates increase by 57%

Price target decreased to €29.40

Price target decreased to €31.42

Insufficient new directors

Carmat SA announced that it expects to receive €36.46431 million in funding from a group of investors

Insufficient new directors

Consensus revenue estimates increase by 11%

Consensus revenue estimates fall by 22%

Price target decreased to €32.50

CARMAT Announces the Completion of Its Investigations on Previously Identified Quality Issues

Health Check: How Prudently Does Carmat (EPA:ALCAR) Use Debt?

CARMAT Announces a New Commercial Implant of Its Aeson® Artificial Heart at University Medical Center Schleswig-holstein in Kiel, Germany

CARMAT Announces the First Human Implant of Its Total Artificial Heart in the United States

Increases to Carmat SA's (EPA:ALCAR) CEO Compensation Might Cool off for now

Carmat (EPA:ALCAR) Is Carrying A Fair Bit Of Debt

New 90-day high: €33.95

CARMAT Receives U.S. Food and Drug Administration Approval to Use the New Version of Its Artificial Heart in the U.S. Early Feasibility Study

CARMAT Appoints Professor Christian Latrémouille as Director of Surgical Affairs

Carmat SA to Report Fiscal Year 2020 Results on Feb 10, 2021

Carmat SA Receives the CE Marking for Its Total Artificial Heart

Price target raised to €35.06

New 90-day high: €33.00

New 90-day high: €24.35

CARMAT Provides Update on the US Early Feasibility Study

New 90-day high: €21.50

New 90-day low: €17.88

マネジメント基準チェック /24